Latest Redmile Group, LLC Stock Portfolio
$1.65Billion– No. of Holdings #63
Redmile Group, LLC Performance:
2024 Q2: -20.03%YTD: -10.5%2023: -0.75%
Performance for 2024 Q2 is -20.03%, and YTD is -10.5%, and 2023 is -0.75%.
About Redmile Group, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Redmile Group, LLC reported an equity portfolio of $1.7 Billions as of 30 Jun, 2024.
The top stock holdings of Redmile Group, LLC are KRYS, FOLD, NRIX. The fund has invested 11.3% of it's portfolio in KRYSTAL BIOTECH INC and 6.4% of portfolio in AMICUS THERAPEUTICS INC.
The fund managers got completely rid off DECIPHERA PHARMACEUTICALS IN (DCPH), ABBOTT LABS (ABT) and ALIGN TECHNOLOGY INC (ALGN) stocks. They significantly reduced their stock positions in ENTRADA THERAPEUTICS INC (TRDA), STEREOTAXIS INC (STXS) and KRYSTAL BIOTECH INC (KRYS). Redmile Group, LLC opened new stock positions in ATARA BIOTHERAPEUTICS INC (ATRA). The fund showed a lot of confidence in some stocks as they added substantially to INVIVYD INC (ADGI), ESTABLISHMENT LABS HLDGS INC (ESTA) and REPLIMUNE GROUP INC (REPL).
The top stock holdings of Redmile Group, LLC are KRYS, FOLD, NRIX. The fund has invested 11.3% of it's portfolio in KRYSTAL BIOTECH INC and 6.4% of portfolio in AMICUS THERAPEUTICS INC.
The fund managers got completely rid off DECIPHERA PHARMACEUTICALS IN (DCPH), ABBOTT LABS (ABT) and ALIGN TECHNOLOGY INC (ALGN) stocks. They significantly reduced their stock positions in ENTRADA THERAPEUTICS INC (TRDA), STEREOTAXIS INC (STXS) and KRYSTAL BIOTECH INC (KRYS). Redmile Group, LLC opened new stock positions in ATARA BIOTHERAPEUTICS INC (ATRA). The fund showed a lot of confidence in some stocks as they added substantially to INVIVYD INC (ADGI), ESTABLISHMENT LABS HLDGS INC (ESTA) and REPLIMUNE GROUP INC (REPL).
Redmile Group, LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Redmile Group, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Redmile Group, LLC made a return of -20.03% in the last quarter. In trailing 12 months, it's portfolio return was -8.79%.
New Buys
| Ticker | $ Bought |
|---|---|
| atara biotherapeutics inc | 3,844,300 |
New stocks bought by Redmile Group, LLC
Additions
| Ticker | % Inc. |
|---|---|
| invivyd inc | 112 |
| establishment labs hldgs inc | 86.31 |
| replimune group inc | 49.12 |
| intuitive surgical inc | 34.85 |
| cogent biosciences inc | 21.13 |
| annexon inc | 16.8 |
| neurogene inc | 8.38 |
| pliant therapeutics inc | 3.63 |
Additions to existing portfolio by Redmile Group, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| entrada therapeutics inc | -56.3 |
| stereotaxis inc | -36.28 |
| krystal biotech inc | -32.3 |
| cytokinetics inc | -30.78 |
| boston scientific corp | -30.43 |
| immunovant inc | -25.73 |
| 89bio inc | -22.91 |
| amicus therapeutics inc | -20.08 |
Redmile Group, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| deciphera pharmaceuticals in | -83,316,200 |
| evolent health inc | -22,270,000 |
| elanco animal health inc | -11,005,900 |
| atara biotherapeutics inc | -6,428,740 |
| progyny inc | -12,241,000 |
| abbott labs | -29,821,100 |
| apellis pharmaceuticals inc | -9,110,900 |
| align technology inc | -28,612,700 |
Redmile Group, LLC got rid off the above stocks
Sector Distribution
Redmile Group, LLC has about 88.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 88.7 |
| Others | 11.1 |
Market Cap. Distribution
Redmile Group, LLC has about 5.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 43.2 |
| MID-CAP | 31.4 |
| UNALLOCATED | 14.1 |
| LARGE-CAP | 5.7 |
| MICRO-CAP | 5.4 |
Stocks belong to which Index?
About 79.8% of the stocks held by Redmile Group, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 74.1 |
| Others | 20.2 |
| S&P 500 | 5.7 |
Redmile Group, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Redmile Group, LLC
Redmile Group, LLC has 63 stocks in it's portfolio. About 45.8% of the portfolio is in top 10 stocks. IMNM proved to be the most loss making stock for the portfolio. NRIX was the most profitable stock for Redmile Group, LLC last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 1.54 | 8,253,320 | 25,420,200 | unchanged | 0.00 | ||
| ABT | abbott labs | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACHL | achilles therapeutics plc | 0.08 | 1,608,090 | 1,310,590 | unchanged | 0.00 | ||
| ADAP | adaptimmune therapeutics plc | 0.04 | 715,607 | 697,645 | unchanged | 0.00 | ||
| ADCT | adc therapeutics sa | 2.92 | 15,269,200 | 48,250,700 | unchanged | 0.00 | ||
| ADGI | invivyd inc | 0.20 | 3,065,710 | 3,372,280 | added | 112 | ||
| AKRO | akero therapeutics inc | 2.29 | 1,614,470 | 37,875,500 | reduced | -13.14 | ||
| ALGN | align technology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALLK | allakos inc | 0.19 | 3,077,830 | 3,077,830 | reduced | -10.82 | ||
| ALVR | allovir inc | 0.08 | 1,907,970 | 1,380,030 | unchanged | 0.00 | ||
| ALXO | alx oncology hldgs inc | 1.47 | 4,036,450 | 24,339,800 | reduced | -6.7 | ||
| ANNX | annexon inc | 1.90 | 6,427,460 | 31,494,600 | added | 16.8 | ||
| APLS | apellis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARDX | ardelyx inc | 0.84 | 1,881,500 | 13,941,900 | reduced | -14.27 | ||
| ATRA | atara biotherapeutics inc | 0.23 | 452,270 | 3,844,300 | new | |||
| ATRA | atara biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AUGX | augmedix inc | 0.87 | 16,380,300 | 14,414,700 | unchanged | 0.00 | ||
| BEAM | beam therapeutics inc | 2.41 | 1,703,060 | 39,902,700 | reduced | -9.39 | ||
| BPMC | blueprint medicines corp | 0.62 | 94,405 | 10,175,000 | reduced | -16.5 | ||
| BSX | boston scientific corp | 1.82 | 390,253 | 30,053,400 | reduced | -30.43 | ||